Results 121 to 130 of about 24,853 (244)

Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3

Blood Advances
: Azole antifungal agents, commonly used for preventing invasive fungal infections in graft-versus-host disease (GVHD), are known to affect ruxolitinib metabolism.
Zahra Mahmoudjafari, Emily Kintsch, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli, Robert Zeiser   +6 more
doaj   +1 more source

ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Bone Marrow Transplantation
Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib and extracorporeal photophoresis (ECP).
O. Penack, C. Peczynski, W. Boreland, Jessica Lemaitre, H. C. Reinhardt, Ksenia Afanasyeva, D. Avenoso, T. Holderried, B. Kornblit, E. Gavriilaki, Carmen Martínez, P. Chiusolo, M. Mico', E. Daguenet, S. Wichert, Hakan Ozdogu, A. Piekarska, F. Kinsella, G. Basak, H. Schoemans, C. Koenecke, I. Moiseev, Z. Perić   +22 more
semanticscholar   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes

Frontiers in Transplantation
BackgroundAdoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and synergize with ruxolitinib, Jak2 inhibitor, to improve outcomes.MethodsUCB ...
Ke Zeng, Hongbing Ma, Meixian Huang, Mi-Ae Lyu, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar   +6 more
doaj   +1 more source

Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies

American Journal of Clinical Dermatology
Atopic dermatitis (AD) is associated with itch, skin pain, sleep disturbances, and diminished quality of life (QoL). Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated efficacy and safety in adults and adolescents with mild-to-moderate ...
E. Simpson, M. Augustin, D. Thaçi, L. Misery, April W. Armstrong, A. Blauvelt, K. Papp, Jacek C Szepietowski, M. Boguniewicz, S. Kwatra, H. Kallender, D. Sturm, Haobo Ren, L. Kircik   +13 more
semanticscholar   +1 more source

Multilingual Digital Search Behavior Reveals Cultural Disparities in Vitiligo Information Needs in Germany

International Journal of Dermatology, EarlyView.
Multilingual vitiligo‐related Google search queries in Germany (October 2019–May 2023) were extracted and thematically coded across German, English, Turkish, Arabic, Russian, and Polish. Relative patterns highlighted language‐specific emphases in treatment information, camouflage, depigmentation, psychosocial burden, and faith/home‐remedy terms ...
Lilian Rauch, Christine Gasteiger, Markus Böhm, Georg Pliszewski, Tilo Biedermann, Alexander Zink   +5 more
wiley   +1 more source

Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections

Journal of Fungi
Ruxolitinib, a selective inhibitor of Janus kinases, is a standard treatment for intermediate/high-risk myelofibrosis (MF) but is associated with a predisposition to opportunistic infections, especially herpes zoster.
Chia-Yu Chiu, Teny M. John, Takahiro Matsuo, S. Wurster, Rachel S. Hicklen, R. Khattak, E. Ariza-Heredia, P. Bose, D. Kontoyiannis   +8 more
semanticscholar   +1 more source

Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell–Dendritic Cell Interaction

Immunology, EarlyView.
During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu, Jan Gärtig, Stephan Eiber, Stefan Moder, Raffael Thaler, Matthias Thaler, Juliane Gruen, Marlies Vornhülz, Kevin Bahner, Luana Messa, Benjamin Kühnemuth, Jennifer Müller, Konstantin Schnell, Antonia Beimert, Carolin Perleberg, Natascha Röhrle, Maximilian Martin Ludwig Knott, Linda Hammann, Vanessa Wittmann, Patrick Layritz, Moritz Rapp, Carole Bourquin, Julia Mayerle, Stefan Endres, David Anz   +24 more
wiley   +1 more source

Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury

Neural Regeneration Research
The inflammatory microenvironment and neurotoxicity can hinder neuronal regeneration and functional recovery after spinal cord injury. Ruxolitinib, a JAK-STAT inhibitor, exhibits effectiveness in autoimmune diseases, arthritis, and managing inflammatory ...
Jiang Cao, Xiao Yu, Jingcheng Liu, Jiaju Fu, Binyu Wang, Chaoqin Wu, Shen Zhang, Hongtao Chen, Zi Wang, Yinyan Xu, Tao Sui, Jie Chang, Xiaojian Cao   +12 more
semanticscholar   +1 more source

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study

Annals of Hematology
Chronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has been approved by
Yuqing Tu, Lingyi Yang, Yaxin Cheng, Yanming Zhang, Yinghao Lu, Shushu Xu, Xiaoli Li, Mimi Xu, Mengqi Xiang, Yi Fan, Yuhua Ru, Yang Xu, Feng Chen, Xiaojin Wu, Yulian Zheng, Fei Li, Yue Han, Xiaowen Tang, Huiying Qiu, Miao Miao, Ye Zhao, Xiaoyu Zhu, Depei Wu, Jia Chen   +23 more
doaj   +1 more source